Sanofi reports positive insulin trial data

Sanofi's investigational insulin product U300 has demonstrated its safety and efficacy in a new clinical trial.

Full results from the Edition II study have been presented at the International Diabetes Federation 2013 World Diabetes Congress in Melbourne, showing that the new product demonstrated similar blood sugar control to Sanofi's established diabetes therapy Lantus.

Moreover, 23 percent fewer type 2 diabetes patients experienced night-time low blood sugar levels when using U300 in the phase III clinical study, results from which were consistent with those of the earlier Edition I trial.

U300 also met its primary endpoint goals in the associated Edition III, Edition IV and Edition JP 1 trials.

Pierre Chancel, senior vice-president for global diabetes at Sanofi, said: "We are encouraged by these results, which suggest that U300 could be a viable treatment option for a wide range of people with type 1 and type 2 diabetes."

This comes after the company launched a new diabetes management app for type 1 diabetes patients in association with Ayogo Health and Diabetes UK last week.